MétaCan
Menu
Back to cohort

Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

2018· article· en· W2891881749 on OpenAlexaff
Matteo Lambertini, Samuel Martel, Christine Campbell, Sébastien Guillaume, Florentine Hilbers, Uwe Schuehly, Larissa A. Korde, Hatem A. Azim, Serena Di Cosimo, Richard C. Tenglin, Jens Huober, José Baselga, Alvaro Moreno‐Aspitia, Martine Piccart, Richard D. Gelber, Evandro de Azambuja, Michail Ignatiadis

Bibliographic record

VenueJournal of Clinical Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicChronic Myeloid Leukemia Treatments
Canadian institutionsHôpital Fleurimont
Fundersnot available
KeywordsMedicinePregnancyTrastuzumabBreast cancerLapatinibInternal medicineGestationCancerGynecologyObstetrics

Abstract

fetched live from OpenAlex

10065 Background: Limited data exist on the safety of using targeted agents in pregnant cancer pts. So far, only retrospective studies assessed the prognosis of pts having a pregnancy after prior EBC with no data in HER2+ pts. We aimed to evaluate the outcome of pregnancies occuring during or following T and/or L and the prognostic effect of having a pregnancy in HER2+ EBC pts. Methods: NeoALTTO and ALTTO were randomized phase 3 trials in HER2+ EBC pts. In both trials, pregnancy information was prospectively collected. Pregnancy outcomes were compared between pts unintentionally exposed to T and/or L during gestation (exposed group) and those who got pregnant following T and/or L completion (not-exposed group). In the ALTTO trial, disease-free (DFS) and overall survival (OS) of pregnant pts were compared to those of pts ≤40 years without subsequent pregnancy with the Extended Cox Model With Time-Varying Covariates to account for guarantee-time bias. Results: Out of 455 and 8,381 pts included in NeoALTTO and ALTTO, 92 pts (7 in NeoALTTO and 85 in ALTTO) had a pregnancy at a median age of 33 years (range 23-40). Pregnancy outcomes are reported in the table No difference in DFS (HR 1.24; 95% CI 0.58-2.6) or OS (HR 0.53; 95% CI 0.13-2.17) was observed between young pts with (n = 85 pts) or without (n = 1,392 pts) a pregnancy. Conclusions: Despite fewer live births were described in the exposed group, unintentional exposure to T and/or L during gestation does not seem to affect newborns’ outcomes upon treatment discontinuation. Having a pregnancy after HER2+ EBC does not appear to impact on DFS or OS. These data are of high relevance to counsel young EBC pts facing pregnancy-related issues. Clinical trial information: NCT00490139. Exposed Group n = 17 pts Not-exposed Group n = 75 pts Completed pregnancy 7 (41%) 52 (69%) Induced abortion 10 (59%) 7 (9%) Spontaneous abortion 0 10 (13%) Ongoing/unknown 0 6 (8%) Live births 7 (41%) 54 (72%) Congenital anomalies 0 1 (2%) Oligohydramnios 0 0 Gestational week at delivery (range) 38.5 (34-39) 39 (38-40) Apgar score (range) 9 (9-9) 9 (9-10) Newborn weight, g (range) 3,145 (2,880-3,776) 3,440 (3,016-3,710) Newborn length, cm (range) 50 (49-52.5) 51 (49-52.5)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.064
GPT teacher head0.391
Teacher spread0.327 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicChronic Myeloid Leukemia TreatmentsFrench-language works237,207